Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note released on Friday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 0.9 %

NASDAQ:AXDX opened at $1.10 on Friday. The stock has a 50 day moving average of $1.62 and a two-hundred day moving average of $1.54. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $4.28. The firm has a market cap of $27.55 million, a P/E ratio of -0.38 and a beta of 0.56.

Insider Buying and Selling

In related news, Director John Patience purchased 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $1.57 per share, with a total value of $314,000.00. Following the completion of the acquisition, the director now owns 653,224 shares in the company, valued at $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 43.60% of the stock is currently owned by company insiders.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics as of its most recent SEC filing. Institutional investors and hedge funds own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.